公开(公告)号：WO9955385A3

公开(公告)日：2000-03-16

申请号：PCT/DE9901237

申请日：1999-04-27

Applicant: BERGTER WOLFGANG ,  BERGTER INGRID CORINA

Inventor： BERGTER WOLFGANG ,  BERGTER INGRID-CORINA

IPC: A61K51/10 ,  A61K51/08

CPC classification number: A61K51/1006

Abstract: The invention relates to radioimmunoconjugates for the in-vivo elimination of virus-replicating cells in patients infected with the hepatitis C virus (HCV). The inventive radioimmunoconjugates are characterized in that they contain, as immunologically active components, (a) a monoclonal antibody or the antigen-binding fragment thereof directed against a viral or virus-induced antigen expressed on the plasma membrane of HCV-infected cells; (b) a receptor molecule or a fragment of the receptor molecule with an affinity to an epitope of the surface glycoproteins E1 and/or E2, or; C) a fragment of the receptor molecule, said fragment being modified by random or selective mutagenesis, with an affinity to an epitope of the surface glycoproteins E1 and/or E2. In addition, the radioimmunoconjugates are characterized in that they contain, as radioactive components, a radioisotope having a shorter half-life and a lower range, for example, d) J, or e) P, or f) Y, or g) Sr. The radioimmunoconjugates are contained together with pharmaceutical supporting materials and/or auxiliary agents.

Abstract translation: 用于在HCV感染患者的病毒复制的细胞的体内消除放射性免疫缀合物，其特征在于它BZY作为免疫学活性组分a）的单克隆抗体，其抗原结合片段以一个对病毒或质膜HCV感染的细胞中表达的病毒诱导的 抗原，或b）一个RezeltormolekülBZV具有亲和力的受体分子的表面糖蛋白E1和/或E2，或一个表位的片段c）中通过用表面糖蛋白E1和/或E2的einemm表位亲和力受体分子的随机或靶向诱变片段的修饰 并且它们<90> Y，或者含有克）<89>以Sr为放射性组分是具有短的半衰期和短程放射性同位素，例如，d）<131> J或E）<32> P，或f）。 与药用载体和/或赋形剂包括沿。

公开(公告)号：WO0000223A3

公开(公告)日：2000-02-17

申请号：PCT/DE9901894

申请日：1999-06-29

Applicant: BERGTER WOLFGANG

Inventor： BERGTER WOLFGANG

IPC: A61K51/00 ,  A61K39/395 ,  A61K51/10 ,  A61K103/00 ,  A61K103/10 ,  A61P1/16 ,  A61P31/12 ,  A61P35/00

CPC classification number: A61K51/1006 ,  A61K51/1027 ,  A61K51/1093

Abstract: The invention relates to a pharmaceutical preparation comprising a radioimmunological conjugate (RIK) for in-vivo elimination of virus-replicating cells in HIV-1, HIV-2, HIV-3, HTLV-1, HTLV-2, HBV, HCV, HDV, CMV, EBV, HHV8 infections and in other chronic virus infections. The radioimmunological conjugate is characterized in that it contains, as immunologically effective constituents; d) a monoclonal antibody or the antigen-binding fragment thereof against a viral or virus-induced antigen expressed on the plasma membrane of virus-infected cells, or; e) a receptor molecule or the fragment thereof with an affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells; or f) a fragment of the cellular receptor molecule, said fragment being modified by mutagenesis, with an affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells. Said conjugate is also characterized in that it contains d) an alpha emitter or a beta emitter as a radioactive constituent. The inventive pharmaceutical preparation also optionally comprises a pharmaceutical carrier and/or adjuvant.

Abstract translation: 描述的本发明涉及包含放射性免疫缀合物（RIK）用于体内消除virusreplizierender细胞在HIV-1，HIV-2，HIV-3，HTLV-1，HTLV-2，HBV的药物组合物 ，HCV，HDV，CMV，EBV，HHV8-和其它慢性病毒感染，其特征在于，它被表示为单克隆抗体免疫学上有效组分d）或针对在质膜上的病毒感染病毒的细胞中的抗原结合片段 或病毒诱导的抗原，或e）的受体分子或与亲和它们的片段用于在受感染的细胞的质膜上表达的病毒结构蛋白的表位，或f）一个由具有亲和力的细胞受体分子的诱变片段用于感染在质膜上的细胞的表位修饰 表达病毒结构蛋白，并且它含有放射性成分d）α发射体或β发射体 和任选的药物载体和/或赋形剂。

公开(公告)号：WO9954954A2

公开(公告)日：1999-10-28

申请号：PCT/DE9901177

申请日：1999-04-15

Applicant: BERGTER WOLFGANG ,  BERGTER INGRID CORINNA

Inventor： BERGTER WOLFGANG ,  BERGTER INGRID CORINNA

IPC: A61K51/00 ,  A61K51/08 ,  A61P31/18 ,  C07K14/705 ,  H01Q

CPC classification number: A61K51/08

Abstract: The disadvantages of standard HIV therapies are as follows: currently used medicaments must be taken in large quantities each day during an entire lifetime according to a strict timetable and have a large number of side effects. Traditional medicaments only manage to restrict virus replication. Host cells infected with HIV are not eliminated. For this reason it was not previously possible to cure HIV infections. The current application describes, as an additional application to PCT patent application (PCT/DE99/00598) dated 8.3.99, radio-immunological pharmaceuticals consisting of a CD4 molecule or a fragment derived therefrom and a radionuclide for in-vivo elimination of HIV replicating cells in HIV-1 and HIV-2 infected patients. The combination of HIV affine CD4 receptor molecules or fragments with radionuclides for therapeutic purposes, especially for use in radioimmunological anti-HIV therapy is totally novel. The radioimmunological pharmaceuticals are to be administered intravenously to HIV-1 or HIV-2 infected patients once or in several cycles in order to cause sustained damage to HIV replicating cells in a targeted manner so that the latter can be fully eliminated.

Abstract translation: 在HIV-标准疗法的缺点包括这样的事实，目前使用的药物是大量采取每日严格的时间表生活，并有许多副作用。 在另一方面，传统的药物只会导致病毒复制的限制。 艾滋病毒感染的宿主细胞没有消除。 出于这个原因，HIV感染是不能治愈。 本专利申请描述了作为用于日1999年3月8日（PCT / DE99 / 00598）放射免疫测定药物由CD4分子或衍生的片段和用于体内消除HIV-复制的细胞中HIV-1放射性核素的PCT专利申请的附加应用 - 和HIV-2感染的患者。 是新颖的缀合HIV亲和力受体CD4分子或其片段与放射性核素用于治疗目的，特别是使用放射免疫疗法的抗HIV感染症在所有。 这种放射免疫药物是静脉给药一次或几次循环HIV-1和/或HIV-2病毒感染者损坏针对性如此强烈，他们完全消除HIV复制的宿主细胞。

公开(公告)号：WO02092136A3

公开(公告)日：2003-09-18

申请号：PCT/DE0201606

申请日：2002-05-03

Applicant: BERGTER WOLFGANG ,  KOBILKE HARTMUT ,  SROKA JOACHIM

Inventor： BERGTER WOLFGANG ,  KOBILKE HARTMUT

IPC: G01N33/531 ,  A61K39/395 ,  A61K41/00 ,  A61K47/48 ,  A61K51/00 ,  A61K51/10 ,  A61P7/02 ,  A61P29/00 ,  A61P31/04 ,  A61P35/00 ,  A61P37/02 ,  A61K49/00

CPC classification number: B82Y5/00 ,  A61K41/0057 ,  A61K41/0071 ,  A61K47/6898 ,  A61K51/1006 ,  A61K51/1027 ,  A61K51/1036 ,  A61K51/1093

Abstract: The invention relates to immunoconjugates made of egg-yolk antibodies (IgY), the production and use thereof in diagnoses and therapy. The aim of the invention is to provide alternative products to traditional immunoconjugates for use in diagnoses and therapy. The inventive immunoconjugates are superior to monoclonal antibodies and immune serums from mammals in addition to IgY preparations from conventional hens in terms of purity and antigen targeting. The invention seeks to avoid the formation of human anti-IgY antibodies as far as possible, and to produce immunoconjugates in large quantities at a low price in a manner which is compatible with animal welfare. This is achieved by polyclonal IgY conjugates from intact egg-yolk antibodies (IgY), IgY fragments, Fab constructions or humanized egg-yolk antibodies form SPF hens, preferably from transgenic SPF hens. The antibodies or antibody fragments are conjugated as immunologically effective components with at least one other component such as a signaling substance, an active substance or an amplifier module.

Abstract translation: 本发明涉及一种从蛋黄抗体（IgY），任何在诊断和治疗中的封装和应用免疫偶联物。 本发明的目的是提出替代产品，以用于诊断和治疗用途的传统免疫缀合物。 新颖的免疫缀合物都优于单克隆从哺乳动物和从常规鸡的IgY制剂的抗体和免疫血清中的纯度和抗原靶向条款。 也应避免人抗IgY抗体抗体的形成，和免疫缀合物应来制备人性化和成本效益的大批量。 该目的通过多克隆IgY抗体缀合物从完整蛋黄抗体（IgY），任何的IgY片段实现的Fab构建体或从SPF鸡胚人源化蛋黄抗体，优选从转基因SPF鸡胚。 所述抗体或抗体片段将被缀合与至少一种另外的组分免疫学活性成分，其可以是药物或增强分子是信号物质。

公开(公告)号：WO9945969A2

公开(公告)日：1999-09-16

申请号：PCT/DE9900598

申请日：1999-03-05

Applicant: BERGTER WOLFGANG ,  BERGTER INGRID CORINA

Inventor： BERGTER WOLFGANG ,  BERGTER INGRID-CORINA

IPC: A61K51/00 ,  A61K39/395 ,  A61K51/10

CPC classification number: A61K51/1039

Abstract: The invention relates to a radioimmuno-pharmacon for treating the HIV-1 infection. The disadvantages of standard HIV therapies are that the medicaments currently used must be taken daily in large quantities (approx. 30 tablets per day), in accordance with a strict timetable and for the rest of the patient's life, and that they cause numerous side effects. In addition, conventional medicaments only reduce the replication of the virus. They do not eliminate the host cells infected with HIV and therefore do not cure the HIV infection. The inventive radioimmuno-pharmacon consists of a monoclonal antibody and a radionuclide for eliminating HIV-replicating cells in patients infected with HIV-1 in vivo after the virus burden has been reduced with an antiretroviral therapy and optionally, with the added protection of a host cell transplantation and with medicamentous protection of thyroid activity. According to the invention, this radioimmuno-pharmacon is administered to the HIV-1-infected patient intravenously, once or in several cycles. It targets and inflicts lasting damage on the host cells in order to eliminate as near to all of them as possible. The aim is to heal the HIV infection or at least slow down the progression of the disease.

Abstract translation: 在HIV-标准疗法的缺点包括目前大量使用对生命的药品日常的事实（每天约30粒），应采取按照严格的时间表，并有许多副作用。 在另一方面，常规药物只能导致病毒复制的减少。 艾滋病毒感染的宿主细胞没有消除，因此，HIV感染没有痊愈。 本专利申请描述了一种放射免疫测定法药物组成的单克隆抗体，并在体内消除HIV-复制的细胞中HIV-1感染的患者通过用抗逆转录病毒治疗与干细胞和medikamentösem的保护，减少病毒载量以及任选的放射性核素 保护甲状腺的功能。 此放射免疫测定药物应一次或在几个循环HIV-1感染的患者静脉内施用并且具体HIV复制的宿主细胞，因为所有的宿主细胞被消除，从而长期损害。 我们的目标是治愈HIV感染，或至少疾病进展的延迟。